Начало・Списък с акции・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Затворен

СекторЗдравеопазване

212.12 1.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

206.71

Максимум

218

Ключови измерители
By Trading Economics
Приходи	-36M -65M
Продажби	-4.8M 191M
EPS	-1.26
Марж на печалбата	-33.756
Служители	1,220
EBITDA	-36M -61M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+35.28% upside

Дивиденти
By Acuity
Следващи печалби	10.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.6B 12B
Предишно отваряне	211.11
Предишно затваряне	212.12

Настроения в новините

By Acuity

58%

42%

276 / 340 Класиране в Healthcare

Axsome Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 22:16 ч. UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31.07.2026 г., 22:01 ч. UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30.07.2026 г., 19:28 ч. UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29.07.2026 г., 22:01 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28.07.2026 г., 19:51 ч. UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27.07.2026 г., 20:14 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24.07.2026 г., 23:51 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22.07.2026 г., 19:11 ч. UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21.07.2026 г., 19:51 ч. UTC

Social Media

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20.07.2026 г., 21:21 ч. UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Сравнение с други в отрасъла

Ценова промяна

Axsome Therapeutics Inc Прогноза

Ценова цел

By TipRanks

35.28% нагоре

12-месечна прогноза

Среден 285.5 USD 35.28%

Висок 380 USD

Нисък 242 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Axsome Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Axsome Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

276 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.